Stryker Q2 Preview: Deferred Orders Recovery Meets Lofty Valuation

What happened

Stryker heads into Q2 earnings with robotic surgery momentum and a likely bounce from Q1 deferred orders. The Zacks article anticipates a solid recovery, driven by strong procedure demand and Mako installs, which could push results above expectations. However, the DeepValue master report highlights that the stock is already priced for perfection at ~46x earnings, leaving minimal margin of safety versus a DCF-backed estimate near $124. While the short-term narrative is constructive, looming tariff headwinds and integration risks from the Inari acquisition could dampen margins. Thus, even a clean beat may not be enough to justify the current premium, and investors should monitor whether the recovery simply meets already-high expectations.

Implication

Stryker's Q2 is set to benefit from robotic surgery momentum and the return of deferred procedures, which should support above-market revenue growth. However, at ~30x EV/EBITDA and a P/E materially above historical norms, the stock already embeds much of this optimism, leaving little cushion for tariff drag, M&A integration hiccups, or competitive pressure in robotics. With the DCF intrinsic value significantly below the market price, investors should consider trimming into strength rather than chasing a beat that may already be expected.

Thesis delta

The anticipated Q2 recovery reinforces Stryker's near-term operating momentum, but does not alter the overarching concern that the stock is overvalued. The core thesis—high-quality franchise with limited margin of safety—remains intact, and the report's POTENTIAL SELL stance is unchanged.